Claudio Agostinelli

List of Publications by Year
in descending order

136	5,505	101543	88630
papers	citations	36 h-index	70 g-index

142	142	142	7141
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma. Cancer Research, 2010, 70, 1408-1418.	0.9	429
2	The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. Journal of Experimental Medicine, 2012, 209, 1537-1551.	8.5	363
3	Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic Score. Journal of Clinical Oncology, 2006, 24, 2472-2479.	1.6	354
4	Diffuse large B-cell lymphoma. Critical Reviews in Oncology/Hematology, 2013, 87, 146-171.	4.4	323
5	Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. Journal of Clinical Investigation, 2007, 117, 823-834.	8.2	272
6	Gene Expression Analysis of Angioimmunoblastic Lymphoma Indicates Derivation from T Follicular Helper Cells and Vascular Endothelial Growth Factor Deregulation. Cancer Research, 2007, 67, 10703-10710.	0.9	220
7	Myeloid Sarcoma. American Journal of Clinical Pathology, 2009, 132, 426-437.	0.7	198
8	Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. Clinical Cancer Research, 2009, 15, 4415-4422.	7.0	189
9	Alteration of BIRC3 and multiple other NF-Î²B pathway genes in splenic marginal zone lymphoma. Blood, 2011, 118, 4930-4934.	1.4	176
10	Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study. Journal of Clinical Oncology, 2013, 31, 3019-3025.	1.6	129
11	Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood, 2011, 117, 3596-3608.	1.4	128
12	Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. Blood, 2015, 125, 2530-2543.	1.4	125
13	Reproducing the molecular subclassification of peripheral T-cell lymphomaâ€“NOS by immunohistochemistry. Blood, 2019, 134, 2159-2170.	1.4	120
14	CD30 expression in peripheral T-cell lymphomas. Haematologica, 2013, 98, e81-e82.	3.5	117
15	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncology, The, 2017, 18, 1076-1088.	10.7	100
16	IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. Histopathology, 2012, 61, 930-941.	2.9	99
17	Protein Arginine Methyltransferase 5 (PRMT5) Inhibition Induces Lymphoma Cell Death through Reactivation of the Retinoblastoma Tumor Suppressor Pathway and Polycomb Repressor Complex 2 (PRC2) Silencing. Journal of Biological Chemistry, 2013, 288, 35534-35547.	3.4	80
18	Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas. Haematologica, 2008, 93, 1033-1038.	3.5	73

#	Article	IF	Citations
19	Expression of CD52 in peripheral T-cell lymphoma. Haematologica, 2007, 92, 566-567.	3.5	67
20	The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. Lancet Haematology,the, 2016, 3, e467-e479.	4.6	63
21	Primary Bone Marrow Lymphoma. American Journal of Surgical Pathology, 2012, 36, 296-304.	3.7	59
22	Expression of platelet-derived growth factor receptor Î± in peripheral T-cell lymphoma not otherwise specified. Lancet Oncology, The, 2005, 6, 440.	10.7	58
23	Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. Haematologica, 2019, 104, 729-737.	3.5	58
24	Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. Oncotarget, 2015, 6, 6553-6569.	1.8	58
25	Prevalence of <scp>A</scp>chromobacter xylosoxidans in pulmonary mucosaâ€associated lymphoid tissue lymphoma in different regions of <scp>E</scp>urope. British Journal of Haematology, 2014, 164, 804-810.	2.5	54
26	Peripheral T cell lymphomas with follicular T helper phenotype: a new basket or a distinct entity? Revising Karl Lennertâ€™s personal archive. Histopathology, 2011, 59, 679-691.	2.9	51
27	Revising the historical collection of epithelioid cell-rich lymphomas of the Kiel Lymph Node Registry: what is Lennertâ€™s lymphoma nowadays?. Histopathology, 2011, 59, 1173-1182.	2.9	47
28	Pathobiology of Hodgkin Lymphoma. Advances in Hematology, 2011, 2011, 1-18.	1.0	46
29	Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. Oncotarget, 2017, 8, 111836-111846.	1.8	44
30	Potential Pathogenetic Implications of Cyclooxygenase-2 Overexpression in B Chronic Lymphoid Leukemia Cells. American Journal of Pathology, 2005, 167, 1599-1607.	3.8	43
31	Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing. Oncotarget, 2017, 8, 16463-16472.	1.8	43
32	The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies. Therapeutic Advances in Hematology, 2014, 5, 35-47.	2.5	42
33	Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response. OncoImmunology, 2019, 8, e1617588.	4.6	41
34	Successful treatment of disseminated Fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B. Journal of Infection, 2006, 53, e243-e246.	3.3	38
35	Fading With Time of PD-L1 Immunoreactivity in Nonâ€“Small Cells Lung Cancer Tissues: A Methodological Study. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 489-494.	1.2	38
36	Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. Modern Pathology, 2020, 33, 179-187.	5.5	37

#	Article	IF	Citations
37	Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm. Haematologica, 2009, 94, 285-288.	3.5	36
38	CD38, BCLâ€2, PDâ€1, and PDâ€1L expression in nodal peripheral Tâ€cell lymphoma: Possible biomarkers for novel targeted therapies?. American Journal of Hematology, 2017, 92, E1-E2.	4.1	33
39	Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and nonâ€haematopoietic tumours using a newly developed rabbit monoclonal antibody. Histopathology, 2012, 61, 33-46.	2.9	32
40	Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups. Histopathology, 2013, 62, 860-875.	2.9	32
41	slan+ Monocytes and Macrophages Mediate CD20-Dependent B-cell Lymphoma Elimination via ADCC and ADCP. Cancer Research, 2018, 78, 3544-3559.	0.9	31
42	Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. Oncotarget, 2015, 6, 6544-6552.	1.8	31
43	Prognostic Markers in Peripheral T-Cell Lymphoma. Current Hematologic Malignancy Reports, 2010, 5, 222-228.	2.3	30
44	Peripheral T-cell lymphoma classification: the matter of cellular derivation. Expert Review of Hematology, 2011, 4, 415-425.	2.2	30
45	Aberrant expression of <scp>CD</scp>10 and <scp>BCL</scp>6 in mantle cell lymphoma. Histopathology, 2017, 71, 769-777.	2.9	29
46	The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas. Haematologica, 2010, 95, 2056-2062.	3.5	28
47	A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma. Modern Pathology, 2014, 27, 1345-1354.	5.5	28
48	In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2015, 8, 125.	17.0	28
49	Construction and validation of a bone marrow tissue microarray. Journal of Clinical Pathology, 2007, 60, 57-61.	2.0	24
50	Characterization of a New Monoclonal Antibody Against PAX5/BASP in 1525 Paraffin-embedded Human and Animal Tissue Samples. Applied Immunohistochemistry and Molecular Morphology, 2010, 18, 561-572.	1.2	24
51	GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers. BMC Cancer, 2012, 12, 586.	2.6	24
52	Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell Sarcomas. Molecular Cancer Research, 2017, 15, 541-552.	3.4	24
53	Novel markers in pediatric-type follicular lymphoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 771-779.	2.8	22
54	Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma. World Journal of Gastroenterology, 2014, 20, 7049.	3.3	22

#	Article	IF	Citations
55	Lymphoma classification: the quiet after the storm. Seminars in Diagnostic Pathology, 2011, 28, 113-123.	1.5	20
56	Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 575-582.	2.8	20
57	Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. Rheumatology International, 2012, 32, 2209-2213.	3.0	19
58	Intracellular TCR-signaling Pathway. American Journal of Surgical Pathology, 2014, 38, 1349-1359.	3.7	19
59	CD30 expression in neoplastic T cells of follicular T cell lymphoma is a helpful diagnostic tool in the differential diagnosis of Hodgkin lymphoma. Modern Pathology, 2019, 32, 37-47.	5.5	19
60	PD-1 (PDCD1) promoter methylation in Merkel cell carcinoma: prognostic relevance and relationship with clinico-pathological parameters. Modern Pathology, 2019, 32, 1359-1372.	5.5	19
61	IFI16Expression Is Related to Selected Transcription Factors during B-Cell Differentiation. Journal of Immunology Research, 2015, 2015, 1-20.	2.2	18
62	Pathobiology of Anaplastic Large Cell Lymphoma. Advances in Hematology, 2010, 2010, 1-10.	1.0	17
63	Primary cutaneous lymphomas: a reprisal. Seminars in Diagnostic Pathology, 2011, 28, 214-233.	1.5	17
64	The Microenvironmentâ€™s Role in Mycosis Fungoides and SÃ©zary Syndrome: From Progression to Therapeutic Implications. Cells, 2021, 10, 2780.	4.1	17
65	Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda. BMC Clinical Pathology, 2009, 9, 11.	1.8	16
66	Systemic Epstein-Barr-virus-positive T cell lymphoproliferative childhood disease in a 22-year-old Caucasian man: A case report and review of the literature. Journal of Medical Case Reports, 2011, 5, 218.	0.8	16
67	miRNA expression profiling divides follicular dendritic cell sarcomas into two groups, related to fibroblasts and myopericytomas or Castleman's disease. European Journal of Cancer, 2016, 64, 159-166.	2.8	16
68	Pathobiology of Epsteinâ€“Barr virusâ€“driven peripheral T-cell lymphomas. Seminars in Diagnostic Pathology, 2011, 28, 234-244.	1.5	15
69	Vascular endothelial growth factor A (<scp>VEGFA</scp>) expression in mycosis fungoides. Histopathology, 2015, 66, 173-181.	2.9	14
70	Deregulation of miRNAs-cMYC circuits is a key event in refractory celiac disease type-2 lymphomagenesis. Clinical Science, 2020, 134, 1151-1166.	4.3	14
71	PATHOBIOLOGY OF HODGKIN LYMPHOMA. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014040.	1.3	13
72	Minimal residual disease (MRD) in nonâ€Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network. Hematological Oncology, 2019, 37, 368-374.	1.7	13

#	Article	IF	Citations
73	Photodynamic therapy: An option in mycosis fungoides. Photodiagnosis and Photodynamic Therapy, 2017, 20, 107-110.	2.6	12
74	Postâ€radiotherapy vascular lesions of the breast: immunohistochemical and molecular features of 74 cases with longâ€term followâ€up and literature review. Histopathology, 2020, 77, 293-302.	2.9	12
75	Gene Expression Analysis of Follicular Lymphoma Provides a Potential Rationale for Histological Grading Revision.. Blood, 2007, 110, 186-186.	1.4	12
76	Biology and treatment of follicular lymphoma. Expert Review of Hematology, 2009, 2, 533-547.	2.2	11
77	A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report. BMC Cancer, 2018, 18, 645.	2.6	11
78	Physiological PTEN expression in peripheral T-cell lymphoma not otherwise specified. Haematologica, 2009, 94, 1036-1037.	3.5	10
79	Pathobiology of ALK-negative anaplastic large cell lymphoma. Mental Illness, 2011, 3, 5.	0.8	10
80	FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities. BMC Cancer, 2014, 14, 396.	2.6	10
81	Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma. British Journal of Haematology, 2019, 185, 330-334.	2.5	10
82	Lymph node core needle biopsy for the diagnosis of lymphoproliferative disorders: A word of caution. European Journal of Haematology, 2021, 106, 737-739.	2.2	10
83	Immune Microenvironment Features and Dynamics in Hodgkin Lymphoma. Cancers, 2021, 13, 3634.	3.7	10
84	Three-dimensional models: a novel approach for lymphoma research. Journal of Cancer Research and Clinical Oncology, 2022, 148, 753-765.	2.5	9
85	Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion. British Journal of Haematology, 2006, 134, 356-356.	2.5	8
86	Leukocytoclastic Vasculitis Associated with Hairy Cell Leukemia at Diagnosis: A Case Report and Review of the Literature. Tumori, 2016, 102, S124-S127.	1.1	8
87	Erythroderma and non-Hodgkin T-cell lymphoma: what else, apart from Mycosis Fungoides and SÃ©zary syndrome?. European Journal of Dermatology, 2017, 27, 49-53.	0.6	8
88	IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia. Apmis, 2017, 125, 511-522.	2.0	8
89	Reproducibility of SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients. Human Pathology, 2017, 59, 94-101.	2.0	8
90	BCL-2 Expression in Primary Cutaneous Follicle Center B-Cell Lymphoma and Its Prognostic Role. Frontiers in Oncology, 2020, 10, 662.	2.8	8

#	Article	IF	Citations
91	Burkitt lymphoma with a granulomatous reaction: an M1/Th1â€polarised microenvironment is associated with controlled growth and spontaneous regression. Histopathology, 2022, 80, 430-442.	2.9	8
92	Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia. Hematological Oncology, 2022, 40, 58-63.	1.7	8
93	Hsa-miR-15a and Hsa-miR-16-1 Expression Is Not Related to Proliferation Centers Abundance and Other Prognostic Factors in Chronic Lymphocytic Leukemia. BioMed Research International, 2013, 2013, 1-13.	1.9	7
94	BRAF^V^{600E} mutations are found in Richter syndrome and may allow targeted therapy in a subset of patients. British Journal of Haematology, 2015, 170, 282-285.	2.5	7
95	The emerging role of GSKâ€3Î² in the pathobiology of classical Hodgkin lymphoma. Histopathology, 2017, 71, 72-80.	2.9	7
96	Histopathology of B-cell chronic lymphocytic leukemia. Hematology/Oncology Clinics of North America, 2004, 18, 807-826.	2.2	6
97	Paraplegia due to a paravertebral extramedullary haemopoiesis in a patient with polycythaemia vera. Journal of Clinical Pathology, 2006, 60, 581-582.	2.0	6
98	BCL10 down-regulation in peripheral T-cell lymphomas. Human Pathology, 2012, 43, 2266-2273.	2.0	6
99	Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 749-757.	2.8	6
100	Benign TdT-positive cells in pediatric and adult lymph nodes: a potential diagnostic pitfall. Human Pathology, 2018, 81, 131-137.	2.0	6
101	Primary effusion lymphoma associated with Human Herpes Virus-8 and Epstein Barr virus in an HIV-infected woman from Kampala, Uganda: a case report. Journal of Medical Case Reports, 2011, 5, 60.	0.8	5
102	Intrafollicular Epstein-Barr virus-positive large B cell lymphoma. A variant of â€œgerminotropicâ€• lymphoproliferative disorder. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 441-450.	2.8	5
103	Interferon gamma inducible protein 16 (IFI16) expression is reduced in mantle cell lymphoma. Heliyon, 2019, 5, e02643.	3.2	5
104	Role of chromatin assembly factor-1/p60 and poly [ADP-ribose] polymerase 1 in mycosis fungoides. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 961-968.	2.8	5
105	Primary uterine localization of malt lymphoma: A case report and literature review. Leukemia Research, 2011, 35, e185-e187.	0.8	4
106	Single-Agent Lenalidomide Is Effective in the Treatment of a Heavily Pretreated and Refractory Angioimmunoblastic T-Cell Lymphoma Patient. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e119-e122.	0.4	4
107	Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma. Experimental Hematology and Oncology, 2015, 4, 24.	5.0	4
108	BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia . OncoTargets and Therapy, 2019, Volume 12, 4807-4812.	2.0	4

#	Article	IF	Citations
109	Intron 4â€“5 hTERT DNA Hypermethylation in Merkel Cell Carcinoma: Frequency, Association with Other Clinico-pathological Features and Prognostic Relevance. Endocrine Pathology, 2021, 32, 385-395.	9.0	4
110	Myeloid nuclear differentiation antigen: an aid in differentiating lymphoplasmacytic lymphoma and splenic marginal zone lymphoma in bone marrow biopsies at presentation. Human Pathology, 2022, 124, 67-75.	2.0	4
111	Follicular lymphoma: stillSix characters in search of an author?. Leukemia and Lymphoma, 2011, 52, 1655-1667.	1.3	3
112	Plaques and tumors in a patient with refractory SÃ©zary syndrome treated with mogamulizumab. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1263-1265.	0.8	3
113	Molecular Profiling Of Blastic Plasmacytoid Dendritic CELL Neoplasm Reveals A Unique Pattern and Suggests Selective Sensitivity To NF-KB Pathway Inhibition. Blood, 2013, 122, 2502-2502.	1.4	3
114	CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified. Journal of Clinical Pathology, 2011, 64, 83-87.	2.0	2
115	The role of myeloid derived suppressor cells in mycosis fungoides. Cancer Immunology, Immunotherapy, 2018, 67, 1175-1176.	4.2	2
116	Erythroderma with brentuximab vedotin (skin side effects in mycosis fungoides). JDDG - Journal of the German Society of Dermatology, 2021, 19, 99-102.	0.8	2
117	Lymph node core needle biopsy in lymphoproliferative disordersâ€”Authorsâ€™ reply to Alâ€Abbadi and colleagues. European Journal of Haematology, 2021, 107, 297-298.	2.2	2
118	Alopecia areata-like mycosis fungoides: lions for lambs. Italian Journal of Dermatology and Venereology, 2018, 153, 293-295.	0.2	2
119	Paediatric follicular lymphoma. Diagnostic Histopathology, 2016, 22, 6-10.	0.4	1
120	Gene Expression Analysis of Peripheral T-Cell Lymphoma Not Otherwise Specified Reveals the Existance of Two Subgroups Related to Different Cellular Counterparts and Recurrent PDGFRA Deregulation.. Blood, 2005, 106, 1217-1217.	1.4	1
121	Verrucous mycosis fungoides. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 504-505.	0.8	1
122	Granulomatous tattoo reaction in a nivolumab-treated patient. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 530-532.	0.8	1
123	SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients, methodological issue on reproducibility and validityâ€”reply. Human Pathology, 2017, 66, 238-239.	2.0	0
124	Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma â€“ Authors' reply. Lancet Haematology,the, 2017, 4, e64-e66.	4.6	0
125	Cytotoxic Epsteinâ€“Barr virusâ€positive large B cell lymphoma: a regulatory B cellâ€derived neoplasia?. Histopathology, 2017, 70, 650-656.	2.9	0
126	How can we better predict treatment outcomes in classical Hodgkin's lymphoma?. International Journal of Hematologic Oncology, 2017, 6, 65-68.	1.6	0

#	Article	IF	Citations
127	A large mass and erythematousâ€violaceous plaques. JDDG - Journal of the German Society of Dermatology, 2018, 16, 372-375.	0.8	0
128	RALE051: a novel established cell line of sporadic Burkitt lymphoma. Leukemia and Lymphoma, 2018, 59, 1252-1255.	1.3	0
129	Gastric MALT Lymphoma in a Sleeve Gastrectomy Specimen: Case Report and Literature Review. Bariatric Surgical Patient Care, 2018, 13, 90-93.	0.5	0
130	Marker Expression in Peripheral T-Cell Lymphoma Unspecified: Proposal of a Clinical-Pathologic Prognostic Score.. Blood, 2005, 106, 2819-2819.	1.4	0
131	Bone Marrow in Hodgkin Lymphoma and Mimickers. , 2012, , 237-252.		0
132	Signaling Pathways in Rare Lymphomas. , 2014, , 71-95.		0
133	Extramedullary metastatic plasmacytoma in multiple myeloma. Giornale Italiano Di Dermatologia E Venereologia, 2018, 153, 741-743.	0.8	0
134	SÃ©zary Syndrome without erythroderma featuring a CD30+ progression. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 494-495.	0.8	0
135	Cutaneous composite lymphoma consisting of chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma: a unique entity and a putative pathological mechanism for cutaneous composite lymphomas. Italian Journal of Dermatology and Venereology, 2019, , .	0.2	0
136	PD-1 and PD-L1 expression in mycosis fungoides and SÃ©zary Syndrome. Italian Journal of Dermatology and Venereology, 2022, , .	0.2	0